norepinephrine

all catalysts(1)

News(5)

• Aura, Schrödinger trim workforces
  Follow along as BioSpace tracks job cuts and restructuring initiatives.
  biospace · 15h ago
• Psychedelics on the cusp of market breakthrough as clinical, policy support grow
  While there are several FDA-approved psychiatric medicines on the market, many patients still struggle to achieve lasting symptom relief. Psychedelics could help fill this gap.
  biospace · 2d ago
• FDA scientists question Capricor data; Legend CEO steps down
  Capricor shares lost much of their value ahead of a high-stakes advisory committee meeting. Elsewhere, Ying Huang’s resignation extended a stock slide for Legend and AstraZeneca disclosed more pipe…
  biopharma_dive · 15d ago
• Otsuka’s ADHD approval opens up new drug class with $615M opportunity
  Otsuka Pharmaceutical plans to launch Simtriyo—the first norepinephrine, dopamine, serotonin reuptake inhibitor—later this year following scheduling by the U.S. Drug Enforcement Agency.
  biospace · 15d ago
• FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services
  Replimune’s application is the latest example of changing attitudes at the FDA. Elsewhere, Revolution Medicines outlined more RAS-blocking data and a Definium stock offering brought in $800 million.
  biopharma_dive · 1mo ago